Lexeo Therapeutics Partners with Johnson & Johnson to Advance Localized Cardiac Gene Therapy Using Impella Heart Pump Technology
Key Insights
Lexeo Therapeutics has announced a research collaboration with Johnson & Johnson to investigate localized cardiac delivery of gene therapy using Impella heart pump technology.
The partnership aims to concentrate AAV delivery to the heart through cutting-edge administration routes, potentially reducing required doses and improving safety while maximizing therapeutic efficacy.
The collaboration combines Lexeo's expertise in cardiac genetic medicine with Johnson & Johnson's cardiovascular therapeutics capabilities to advance treatments for genetically mediated cardiovascular diseases (search).
Lexeo Therapeutics, a clinical-stage genetic medicine company, has entered into a research collaboration with Johnson & Johnson to explore innovative approaches for localized cardiac gene therapy delivery. The partnership leverages Johnson & Johnson's Impella heart pump technology to potentially revolutionize how gene therapies are administered for cardiovascular diseases (search).
Novel Delivery Approach for Cardiac Gene Therapy
The collaboration focuses on concentrating adeno-associated viral (AAV) delivery directly to the heart through cutting-edge routes of administration using Impella heart pump technology. This approach aims to substantially reduce required AAV doses while improving gene therapy safety and maximizing transgene expression and clinical efficacy.
Impella heart pumps provide direct cardiac unloading to enhance myocardial perfusion, which may help facilitate the delivery of gene therapy to cardiac tissue. This localized delivery method represents a significant advancement in targeting genetically mediated cardiovascular diseases (search).
Strategic Partnership Combining Complementary Expertise
"This collaboration represents an exciting step toward unlocking the full potential of cardiac gene therapy," said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. "By concentrating delivery to the heart with localized routes of administration leveraging Impella heart pumps, we aim to substantially reduce required AAV doses and improve gene therapy safety while maximizing transgene expression and clinical efficacy."
The agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration. The partnership combines Lexeo's leadership in cardiac genetic medicine with Johnson & Johnson's expertise in cardiovascular therapeutics and circulatory technologies.
Lexeo's Cardiovascular Gene Therapy Portfolio
Lexeo Therapeutics is advancing a portfolio of therapeutic candidates that target the underlying genetic causes of cardiovascular conditions. The company's pipeline includes LX2006 for the treatment of Friedreich ataxia cardiomyopathy (search) and LX2020 for the treatment of plakophilin-2 (search) (PKP2 (search)) arrhythmogenic cardiomyopathy (search), among others in devastating diseases with high unmet medical need.
The New York City-based company is dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases (search) are treated, focusing on genetic medicine approaches for conditions with significant unmet medical needs.